AHRQ (Agency for Healthcare Research and Quality) casts doubt on TMR/PMR (transmyocardial revascularisation)/(percutaneous myocardial revascularisation) for angina
This article was originally published in Clinica
Executive Summary
A new Medicare-commissioned technology assessment is highly critical of transmyocardial revascularisation (TMR) and percutaneous myocardial revascularisation (PMR) as a way of treating the crushing pain of angina. The report by the federal Agency for Healthcare Research and Quality (AHRQ) was released ahead of an upcoming Medicare Coverage Advisory Committee meeting on TMR and PMR and could induce Medicare to curtail its coverage of the two technologies.